Pacira BioSciences Stock (NASDAQ: PCRX) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 492.160K |
Day Range | - - - |
52 Wk Range | 25.760 - 48.600 |
Market Cap | $1.186B |
P/E Ratio | 29.326 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 28 |
Short Interest | 11.19% |
Days to Cover | 8.89 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Pacira BioSciences (NASDAQ: PCRX) through any online brokerage.
Other companies in Pacira BioSciences’s space includes: Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE), Tarsus Pharmaceuticals (NASDAQ:TARS) and Neumora Therapeutics (NASDAQ:NMRA).
The latest price target for Pacira BioSciences (NASDAQ: PCRX) was reported by Needham on Tuesday, April 9, 2024. The analyst firm set a price target for 45.00 expecting PCRX to rise to within 12 months (a possible 76.40% upside). 25 analyst firms have reported ratings in the last year.
The stock price for Pacira BioSciences (NASDAQ: PCRX) is $25.51 last updated April 18, 2024 at 7:20 PM EDT.
There are no upcoming dividends for Pacira BioSciences.
Pacira BioSciences’s Q1 earnings are confirmed for Wednesday, May 1, 2024.
There is no upcoming split for Pacira BioSciences.
Pacira BioSciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.